PRLD - Prelude Therapeutics Incorporated - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-155M

Cash

255M

Avg Qtr Burn

-25.29M

Short % of Float

4.54%

Insider Ownership

9.17%

Institutional Own.

84.34%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PRT3645 (CDK4/6 inhibitor) Details Glioblastoma, Head and neck cancer, Non-small cell lung carcinoma, Breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRT543 (PRMT5 inhibitor) Details Solid tumor/s, Myelodysplastic syndrome, Myelofibrosis, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRT3789 Details Non-small cell lung carcinoma, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRT2527 (CDK9 inhibitor) Details Acute myeloid leukemia, Solid tumor/s, Hematologic malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRT1419 (MCL1 inhibitor) Details Hematologic malignancies, Relapsed/refractory acute myeloid leukemia, B-cell malignancies, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRT811 (PRMT5 inhibitor) Details Glioblastoma, Cancer, primary central nervous system lymphomas	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.